After the first dose of FluMist Quadrivalent, 23% of children vaccinated with the 2017-2018 H1N1 LAIV strain developed a fourfold antibody rise, compared to 5% with the 2015-2016 H1N1 LAIV strain.
Just Thursday, CDC officials pinpointed one reason why this flu season has been so brutal: the flu vaccine is only 25 percent effective against H3N2 influenza, which is causing most flu cases this year.
"For the 2018-19 season, immunization providers may choose to administer any licensed, age-appropriate, influenza vaccine (including LAIV, IIV and RIV)". But the company that makes FluMist said on Wednesday that it's reformulated the vaccine, has tested it in 200 kids, and suggests it works better now.
The vaccine remains on the recommended list in Canada and the European Union. 10th, a total of 43 states continued to experience widespread flu activity, down from 48 the week before, according to the latest surveillance report from the U.S. Centers for Disease Control and Prevention.More news: Samsung Galaxy J2 Pro, Galaxy J2 (2017) get price cut in India
More news: Colts, Vinatieri reach one-year deal
More news: Doping: a hockey player in slovenian tested positive
According to an NBC News report, some ACIP members are anxious that an ineffective FluMist will hurt public perceptions, but others argue that the lack of a needle-free option turns kids off getting vaccinated.
The nasal spray version of the flu vaccine popular with children but largely unavailable this season due to questions about its effectiveness is likely to return next fall.
(ACIP) declined to recommend FluMist in 2016 and again for this season, citing studies that showed it only reduced the risk of getting influenza by 3 percent over the past three flu seasons.
But on Wednesday, the panel voted 12-2 to recommend FluMist as an option for the next flu season.
AstraZeneca says it will supply FluMist to the US market next season.